Zhong Nanshan academician team lianhua Qing plague treatment of new coronary pneumonia prospective, randomized, controlled, multi-center clinical research papers published in the international journal "Plant Medicine"

The study was conducted in more than 20 hospitals across the country to treat new coronary pneumonia, and it was not possible to conduct double blindness, taking into account the urgency of epidemic prevention and control; According to the study plan, the selected patients were randomly divided into treatment group and control group (conventional treatment group), with reference to the "new coronavirus pneumonia diagnosis and treatment plan (trial version 4)," the treatment group: routine treatment and even flower plague capsule 4 capsules / times, 3 times / day or particles 1 bag / time, 3 times / day, treatment cycle: 14 daysThe main therapeutic indicators are the main clinical symptoms (fever, fatigue, cough) cure rate, secondary efficacy index for the duration of clinical symptoms, single symptom severity rate and duration, lung CT improvement rate, clinical cure rate, the rate of conversion during the study period, nucleic acid conversion rate and change timeA total of 284 cases were collected in accordance with the study programmetrial data after professional third-party statistical analysis, the results showed that: after 14 days of treatment in the treatment group, the main clinical symptoms (fever, fatigue, cough) cure rate was significantly higher than the control group, in the 7th day of treatment reached 57.7%, the 10th day of treatment reached 80.3%, the 14th day of treatment reached 91.5%Fever, fatigue, cough ingenum duration of single symptoms is also significantly shortened, even the treatment of plague can significantly improve the lung CT imaging abnormality improvement rate, improve the overall clinical cure rateFrom the analysis to reduce the proportion of patients who turned heavy, the treatment group and the control group were significantly lower (2.1% of the plague treatment group and 4.2% of the control group)However, in this clinical trial, even flower plague capsules in the improvement of the new coronary pneumonia nucleic acid transfemininity and shorten the time of transfemininity compared with the control group (conventional treatment group) although shown some advantages, but the difference has not yet reached a statistical significanceFigure 1 General Study Found that theFigure 2 Lianhua Qing plague capsule treatment group significantly shortens the recovery time of symptoms (left- and in-line scenario set; right: in line with the program set)Figure 3 Lianhua Qing plague capsule treatment group significantly improves the rate of symptom cure (full plan set)Figure 4 Lianhua qing plague capsule treatment The adverse events in the study of the group significantly improved the clinical cure rate and shortened the time for CT abnormality recovery (A and C diagrams; B and D graph: conforming to the scheme set)the adverse events in the study were mainly light to moderate, and there was no significant difference between the two groups, and there were no serious adverse events associated with the studythe results of this study were included in the journal Phytomedicine (2020 Sci Journal Division of the Chinese Academy of Sciences) in the journal Phytomedicine (Phytomedicine, Impact Factor 4.18), and is the first forward-looking, randomized, controlled, multi-center clinical study of Chinese medicine to treat new coronavirus infection reported in the international journalThe valuable aspect of this study is that under the circumstances of the epidemic so urgent, Chinese researchers conducted clinical studies in accordance with internationally recognized randomized control standards, confirming the effectiveness of Chinese medicine on the auxiliary treatment of the new crown, represented by lianhua qing plague capsulesOn April 12, 2020, the State Drug Administration issued the "Drug Supplementapplication Approval" on the application for new indications, approved the "Drug Supplement application approval" on the application for new indications, approved the new coronary pneumonia indications increased by the "functional main treatment" item "in the specification" of "the general treatment of new coronary viral pneumonia, can be used for light, common type of fever, cough, fatigue." "Usage dosage" item to increase the "new coronavirus pneumonia light, ordinary treatment 7-10 days" content, indicating that lianhua qing plague new coronas series of research has been highly recognized by the relevant departments of the stateZhong Nanshan academician's team attaches great importance to the development of traditional Chinese medicine, in the early stage of the epidemic on the positive response to the national call, led a number of medical institutions nationwide to carry out a strict design of Chinese medicine screening research and clinical application discussion, and organized the launch of a randomized controlled clinical trial represented by lianhua qing plague capsulesThe publication of the clinical research results of the study of the new coronal pneumonia published by Phytomedicine, a journal with high impact factors in the field of international botany medicine, is also the international recognition and affirmation of the new crown of Chinese medicine prevention and control, which is of great significance to the internationalization of Chinese medicinethe authors of this article are Professor Zhong Nanshan (First Hospital affiliated with Guangzhou Medical University), Professor Jia Zhenhua (National Key Laboratory for Research and Innovation of Chinese Medicine), and the co-authors include Professor Huke (Wuhan University People's Hospital), Guan Weijie Associate Researcher (Guangzhou Medical University Affiliated First Hospital), Professor Bi Ying (Wuhan Red Cross Hospital), Professor Zhang Wei (First Affiliated Hospital of Nanchang University), and co-authors also include Li Lanxuan (Zhejiang University School of Medicine, First Affiliated Hospital)Academician Zhang Boli (First Affiliated Hospital, Tianjin University of Traditional Chinese Medicine), Professor Liu Qingquan (Beijing Chinese Medicine Hospital affiliated with Capital Medical University), Professor Song Yuanlin (Sun Yat-sen Hospital affiliated with Fudan University), Professor Li Sheng (Beijing Ditan Hospital affiliated with Capital Medical University), Professor Duan Zhongping (Beijing You'an Hospital affiliated with Capital Medical University), Professor Zheng Qingshan (Shanghai University of Traditional Chinese Medicine), Professor Yang Zifeng (Guangzhou Respiratory Health Research Institute), DrLiang Jingyi (Guangzhou Respiratory Health Research Institute), Professor Han Mingfeng (Second People's Hospital, Puyang City), Professor Yan Lianguo (Jinyintan Hospital, Wuhan City), Professor Wu Chaomin (Sun Yat-sen Hospital affiliated with Fudan University), and Professor Zhang Yunxuan (Respiratory and Critical Lyo Medical Department, Wuhan University People's Hospital)would like to pay tribute to all patients and health care workers who have participated in this programlinks: https://